Sells prescription medicines for ADHD and moderate-to-severe pain to pharmaceutical wholesalers, which distribute them to pharmacies and other outlets.
10-K for FY2025, filed Feb 26, 2026
The company sells its medicines to wholesalers; payment typically arrives 30 to 90 days after the products are delivered.
10-K for FY2025, filed Feb 26, 2026
10-K for FY2025, filed Feb 26, 2026
FY2025 revenue by product or service ↗$780.6M
10-K for FY2025, filed Feb 26, 2026
$780.6M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Belbuca
Sold outright
10-K for FY2025, filed Feb 26, 2026 |
28%
FY2022: 27%
|
Belbuca, FY2025
$221.7M Sources
|
Sold outright |
|
Xtampza ER
Sold outright
10-K for FY2025, filed Feb 26, 2026 |
26%
FY2022: 30%
|
Xtampza ER, FY2025
$199.3M Sources
|
Sold outright |
|
Jornay PM
Sold outright
10-K for FY2025, filed Feb 26, 2026 |
19% |
Jornay PM, FY2025
$148.9M Sources
|
Sold outright |
|
Nucynta IR
Sold outright
10-K for FY2025, filed Feb 26, 2026 |
15%
FY2022: 24%
|
Nucynta IR, FY2025
$115.3M Sources
|
Sold outright |
|
Nucynta ER
Sold outright
10-K for FY2025, filed Feb 26, 2026 |
10%
FY2022: 16%
|
Nucynta ER, FY2025
$81M Sources
|
Sold outright |
|
Symproic and other
Sold outright
|
1.9% |
Symproic and other, FY2025
$14.5M Sources
|
Sold outright |
Collegium sells mainly to wholesalers, which distribute medicines to pharmacies, health care organizations and government agencies. Its field teams call on health care professionals, while market-access staff work on formulary approval and payor contracts.
10-K for FY2025, filed Feb 26, 2026
10-K for FY2025, filed Feb 26, 2026
These same three customers comprised 34%, 34%, and 29% of revenue during the year ended December 31, 2025; 33%, 33%, and 31% during the…View ↗
Yes. It kept 8 cents of every revenue dollar as net income in FY2025 and turned 42 cents into free cash flow.
10-Q for Q3 FY2026, filed Nov 5, 2026
Open tableView ↗
8-K, filed Aug 6, 2026
Collegium reaffirms its full-year 2026 guidance for JORNAY PM and raises AZSTARYS Revenue, Net and updates its full-year 2026 guidance for…View ↗
8-K, filed May 12, 2026
As previously disclosed, on March 19, 2026, Collegium Pharmaceutical, Inc. (the “Company”), entered into an Equity Purchase Agreement (the…View ↗
Growing. Revenue grew 2.8x in 4 years, from $276.9M in FY2021 to $780.6M in FY2025, about 30% a year.
Added ADHD treatment
The earlier description covers a pain portfolio; the later description adds ADHD treatment through Jornay PM, expanding the business beyond pain management.
10-K for FY2022, filed Feb 23, 2023 10-K for FY2025, filed Feb 26, 2026We are building a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious…View ↗
Competes with Vertex Pharmaceuticals
10-K for FY2025, filed Feb 26, 2026Our industry is characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products. Our…View ↗
Loading...